Preoperative Chemotherapy Holds Promise for Lung Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BUFFALO, NY-Although adjuvant therapies have made important inroads into improving overall survival for many cancer patients, lung cancer patients have not been so fortunate, Robert J. Ginsberg, MD, said at the Roswell Park Surgical Oncology Symposium.

BUFFALO, NY—Although adjuvant therapies have made important inroads into improving overall survival for many cancer patients, lung cancer patients have not been so fortunate, Robert J. Ginsberg, MD, said at the Roswell Park Surgical Oncology Symposium.

“Previous results of surgery alone or surgery with adjuvant therapies using chemotherapy, radiotherapy, or their combinations have been dismal in patients with locally advanced lung cancers,” said Dr. Ginsberg, chief of the Thoracic Service, Memorial Sloan-Kettering Cancer Center. “However, the use of preoperative or induction chemotherapy, followed by surgery, offers a measure of hope to some lung cancer patients.” In certain instances, he said, when a complete response is noted at surgery, survival of up to 60% has been achieved.

Most trials of such therapy have included patients with N2 disease, but, more recently, trials of preoperative chemotherapy have been reported in patients with earlier stage tumors.

Theoretically, the use of preoperative chemotherapy will decrease the size of the primary lung cancer tumor, affect the number of micrometastases, and decrease the odds of seeding cancer cells throughout the chest cavity during the surgical procedure, Dr. Ginsberg said.

“Preoperative chemotherapy offers us the chance to give patients the potential benefits of such therapy while they are fit to receive it. A major problem with lung cancer surgery is the lengthy recovery time. Because of this, many patients cannot receive adequate adjuvant treatment. Treating with systemic therapy initially seems to make a difference,” he said.

Disadvantages for such induction therapy are the delay of the initial surgery, which may disturb patients, and an increase in surgical morbidity. “Although there are some theoretical disadvantages, it appears that such induction therapy is effective, especially if the tumor can be downstaged. We do not know yet if the optimal preoperative treatment is chemotherapy alone or chemotherapy with radiation therapy,” he said.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.